Table 3.
Crude Median Survival for BCP, CP 2006–7, and CP 2002–5 Treated Patients and Hazard Ratios for Overall Survival for BCP vs. CP 2006–7 or CP 2002–5 Adjusting for Patient Characteristics
| Variable | Crude Median Survival (IQR) in months
|
Hazard Ratio (95% CI)
|
|||
|---|---|---|---|---|---|
| BCP | CP 2006–7 | CP 2002–5 | BCP and CP 2006–7 | BCP and CP 2002–5 | |
| Chemotherapy regimen | |||||
|
| |||||
| CP | 8.9 (3.5–19.3) | 8.0 (3.7–17.2) | Reference | Reference | |
|
| |||||
| BCP | 9.7 (4.4–18.6) | 1.01 (0.88–1.15) | 0.94 (0.83–1.06) | ||
|
| |||||
| Age at diagnosis, years | |||||
|
| |||||
| 65–69 | 9.9 (5.5–20.4) | 9.5 (3.4–19.5) | 8.1 (3.7–17.2) | Reference | Reference |
|
| |||||
| 70–74 | 8.7 (4.9–16.8) | 9.8 (4.4–19.0) | 7.8 (3.7–16.7) | 1.03 (0.90–1.18) | 1.07 (0.98–1.18) |
|
| |||||
| 75–79 | 8.5 (3.6–16.7) | 6.8 (3.2–18.5) | 8.1 (3.2–16.2) | 1.10 (0.95–1.27) | 1.10 (0.99–1.21) |
|
| |||||
| 80+ | 13.1 (2.6–21.8) | 9.3 (3.6–20.1) | 8.4 (3.8–17.2) | 1.07 (0.89–1.29) | 1.08 (0.94–1.23) |
|
| |||||
| Gender | |||||
|
| |||||
| Female | 10.9 (5.2–21.5) | 10.3 (4.1–23.0) | 9.0 (3.8–20.5) | Reference | Reference |
|
| |||||
| Male | 8.3 (3.8–15.4) | 7.7 (3.3–16.1) | 7.4 (3.3–14.6) | 1.37 (1.23–1.54) | 1.28 (1.18–1.38) |
|
| |||||
| Race/Ethnicity | |||||
|
| |||||
| Non-Hispanic White | 8.9 (4.1–16.8) | 8.6 (3.5–19.0) | 7.9 (3.5–16.3) | Reference | Reference |
|
| |||||
| Non-Hispanic Black | 10.9 (4.0–22.1) | 9.5 (3.3–17.9) | 8.0 (3.0–18.5) | 0.93 (0.75–1.15) | 0.91 (0.77–1.06) |
|
| |||||
| Other | 16.9 (7.1–25.5) | 11.2 (4.4–20.8) | 9.8 (4.7–21.9) | 0.80 (0.65–0.98) | 0.79 (0.69–0.91) |
|
| |||||
| Marital status | |||||
|
| |||||
| Not married | 8.8 (3.9–19.4) | 8.3 (3.5–17.1) | 7.8 (3.5–16.3) | Reference | Reference |
|
| |||||
| Married | 9.9 (5.0–17.6) | 9.3 (3.5–20.5) | 8.1 (3.7–17.2) | 0.88 (0.78–0.98) | 0.90 (0.83–0.97) |
|
| |||||
| SEER region | |||||
|
| |||||
| Northeast | 8.6 (5.3–15.9) | 9.7 (4.1–19.0) | 8.6 (3.4–18.2) | Reference | Reference |
|
| |||||
| South | 7.1 (2.7–16.2) | 9.1 (3.4–17.5) | 7.3 (3.5–15.8) | 1.03 (0.86–1.23) | 1.09 (0.96–1.23) |
|
| |||||
| Midwest | 9.7 (4.2–15.5) | 7.6 (3.4–17.1) | 7.3 (3.4–14.9) | 0.97 (0.80–1.18) | 1.04 (0.91–1.19) |
|
| |||||
| West | 11.2 (5.5–20.4) | 9.1 (3.4–20.1) | 8.6 (3.8–17.2) | 0.91 (0.76–1.08) | 1.01 (0.90–1.13) |
|
| |||||
| Urban residency | |||||
|
| |||||
| No | 6.3 (2.6–12.6) | 9.0 (3.5–20.7) | 8.4 (3.2–17.4) | Reference | Reference |
|
| |||||
| Yes | 9.9 (4.9–20.0) | 8.9 (3.5–19.0) | 8.0 (3.6–16.9) | 1.08 (0.87–1.34) | 1.06 (0.91–1.23) |
|
| |||||
| Median income (census tract quintile) a | |||||
|
| |||||
| 1 (lowest) | Reference | Reference | |||
|
| |||||
| 2 | 0.97 (0.81–1.16) | 0.90 (0.80–1.02) | |||
|
| |||||
| 3 | 0.83 (0.69–1.02) | 0.94 (0.83–1.07) | |||
|
| |||||
| 4 | 0.87 (0.71–1.06) | 0.94 (0.82–1.07) | |||
|
| |||||
| 5 (highest) | 0.77 (0.64–0.94) | 0.92 (0.80–1.05) | |||
|
| |||||
| College educated (census tract quintile) a | |||||
|
| |||||
| 1 (lowest) | Reference | Reference | |||
|
| |||||
| 2 | 1.04 (0.87–1.24) | 1.04 (0.92–1.18) | |||
|
| |||||
| 3 | 0.94 (0.78–1.14) | 0.99 (0.87–1.12) | |||
|
| |||||
| 4 | 1.04 (0.86–1.27) | 1.06 (0.93–1.21) | |||
|
| |||||
| 5 (highest) | 1.19 (0.96–1.47) | 1.10 (0.95–1.27) | |||
|
| |||||
| Modified Charlson comorbidity score b | |||||
|
| |||||
| 0 | 9.0 (4.2–20.4) | 9.1 (3.5–20.1) | 8.3 (3.8–17.5) | Reference | Reference |
|
| |||||
| 1 | 9.7 (4.2–16.7) | 9.5 (3.4–20.3) | 7.7 (3.3–15.5) | 0.99 (0.87–1.12) | 1.08 (0.99–1.18) |
|
| |||||
| 2+ | 13.8 (4.9–18.4) | 7.1 (3.6–16.3) | 7.4 (3.0–16.5) | 1.17 (1.00–1.38) | 1.08 (0.96–1.22) |
|
| |||||
| Level of differentiation (Tumor grading) | |||||
|
| |||||
| Well/moderately | 11.6 (6.0–35.7) | 13.9 (5.8–30.4) | 11.0 (4.5–22.1) | Reference | Reference |
|
| |||||
| Poorly/no | 7.1 (3.5–14.6) | 7.5 (3.4–18.5) | 7.3 (3.3–16.2) | 1.57 (1.29–1.92) | 1.38 (1.21–1.57) |
|
| |||||
| Unknown | 9.8 (5.0–20.0) | 8.7 (3.4–17.3) | 8.1 (3.6–16.1) | 1.51 (1.25–1.81) | 1.26 (1.11–1.42) |
|
| |||||
| AJCC Stage | |||||
|
| |||||
| IIIB | 12.6 (7.6–21.8) | 13.8 (5.5–27.9) | 10.9 (5.1–23.1) | Reference | Reference |
|
| |||||
| IV | 8.4 (4.1–17.0) | 7.4 (3.2–15.7) | 7.0 (3.0–14.4) | 1.57 (1.38–1.78) | 1.43 (1.32–1.55) |
Abbreviations: IQR, interquartile range; CI, confidence interval; BCP, bevacizumab-carboplatin-paclitaxel; CP 2006–7, carboplatin-paclitaxel (diagnoses 2006–7 when bevacizumab was FDA approved for NSCLC); CP 2002–5, carboplatin-paclitaxel (diagnoses 2002–2005 when bevacizumab was not available (2002–3) or not approved for NSCLC treatment); SEER, Surveillance, Epidemiology and End Results; AJCC, American Joint Committee on Cancer.
The income and education quintiles were constructed when comparing the BCP group to each of the CP controls, and thus, the cutoff values were not the same across these groups. Hence, there was no crude median survival for subgroups of these two variables.
Mordified Charlson comorbidity score was constructed by applying the Deyo adaptation18 of the Charlson comorbidity index,19 modified to exclude cancer diagnoses, to Medicare inpatient, outpatient, and physician claims during the 12-month period extending from 13 months to 1 month before NSCLC diagnosis using lung cancer-specific weights as described by Klabunde et al.20,21